<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02908685</url>
  </required_header>
  <id_info>
    <org_study_id>BP39055</org_study_id>
    <secondary_id>2016-000750-35</secondary_id>
    <nct_id>NCT02908685</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants</brief_title>
  <acronym>SUNFISH</acronym>
  <official_title>A Two Part Seamless, Multi-Center Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      Multi-center, randomized, double-blind, placebo-controlled study to assess the safety,&#xD;
      tolerability, pharmacokinetics, pharmacodynamics, and efficacy of Risdiplam in adult and&#xD;
      pediatric participants with Type 2 and Type 3 SMA. The study consists of two parts, an&#xD;
      exploratory dose finding part (Part 1) of Risdiplam for 12 weeks and a confirmatory part&#xD;
      (Part 2) of Risdiplam for 24 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 20, 2016</start_date>
  <completion_date type="Anticipated">September 2, 2023</completion_date>
  <primary_completion_date type="Actual">September 6, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Selected Part 2 Dose of Risdiplam for Participants With a Body Weight (BW) of &gt;/=20kg</measure>
    <time_frame>Day 1 up to at least 4 weeks on study (Up to CCOD of 25 July 2017)</time_frame>
    <description>The Internal Monitoring Committee (IMC) was responsible for selecting the dose for Part 2 of the study (pivotal dose). An external Independent Data Monitoring Committee (iDMC) reviewed data from Part 1 and confirmed the dose-selection decision of the IMC. The dose for Part 2 selected by the IMC was a dose that: 1.Was judged to be safe and well-tolerated, based on all available safety data from Part 1 and as confirmed by the iDMC; 2. Resulted in an exposure at steady-state below the exposure cap (mean value) of AUC0-24h,ss 2000 ng*h/mL (adjusted for free-fraction, if required); 3. Resulted in an SMN protein increase that was expected to be clinically relevant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Selected Part 2 Dose of Risdiplam for Participants With BW of &lt;20kg</measure>
    <time_frame>Day 1 up to at least 4 weeks on study (Up to CCOD of 25 July 2017)</time_frame>
    <description>The Internal Monitoring Committee (IMC) was responsible for selecting the dose for Part 2 of the study (pivotal dose). An external Independent Data Monitoring Committee (iDMC) reviewed data from Part 1 and confirmed the dose-selection decision of the IMC. The dose for Part 2 selected by the IMC was a dose that: 1.Was judged to be safe and well-tolerated, based on all available safety data from Part 1 and as confirmed by the iDMC; 2. Resulted in an exposure at steady-state below the exposure cap (mean value) of AUC0-24h,ss 2000 ng*h/mL (adjusted for free-fraction, if required); 3. Resulted in an SMN protein increase that was expected to be clinically relevant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change From Baseline in the Total Motor Function Measure 32 (MFM-32) Total Score at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
    <description>The Motor Function Measure 32 (MFM32) is a scale constructed for use in neuromuscular disorders. It comprises 32 items that evaluate physical function in three dimensions: D1 function related to standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and &quot;normally&quot;. The 32 scores are summed and expressed on a 0-100 scale for the MFM32 total score. Higher scores indicate increased motor function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on primary efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage of Participants With Marked Improvement (Defined as &gt;= 3) in the Total Motor Function Measure (MFM32) Score at Month 12</measure>
    <time_frame>At Month 12</time_frame>
    <description>The MFM32 comprises 32 items that evaluate physical function. The scoring of each task uses a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and &quot;normally&quot;. The 32 scores are summed and expressed on a 0-100 scale for the MFM32 total score. A change in MFM32 total score of threshold &gt;/=3 represents marked improvement in this measure. Logistic regression analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change From Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
    <description>The RULM is a 20 items scale that assesses the proximal and distal motor functions of the arm. There is an entry item and the remaining 18 items are scored on the 3 point scale of: 0: cannot complete task independently; 1: modified method but can complete task independently; 2: completes task without any assistance, and with 1 item scored on a 2 point scale of as a can/cannot score with 1 as the highest score. The RULM total score is the sum of 19 items scores with range of 0-37, and the entry item does not contribute to the total score. Higher scores indicate greater upper limb function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on the efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change From Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
    <description>The HFMSE scale contains 33 items, which are scored on a 3-point Likert-type scale (0-2) and summed to derive the total score, with lower scores indicating greater impairment. The HFMSE contains a series of assessments designed to assess important functional abilities, including standing, transfers, ambulation, and proximal and axial function. The overall score is the sum of the scores for all activities with a maximum achievable score of 66. Higher scores indicate greater motor function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on the efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change From Baseline in Forced Vital Capacity (FVC) at Month 12 in Participants Aged 6-25 Years</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
    <description>Spirometry is a pulmonary function test that assesses how the lungs work by measuring how much air moves through the airways. Spirometry was performed by all participants aged 6 or older. Forced vital capacity (FVC) is the total volume that can be exhaled after inhaling maximally. The best % predicted value out of all attempts were used for the analysis. MMRM analysis was performed based on the efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change From Baseline in the Caregiver-Reported SMA Independence Scale (SMAIS) Total Score at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
    <description>The SMA Independence Scale (SMAIS) was developed specifically for SMA participants in order to assess function-related independence. The SMAIS contains 29 items, assessing the amount of assistance required from another individual to perform daily activities such as eating, or bathing. Each item is scored on a 0-4 scale (with an additional option to indicate that an item is non-applicable). The SMAIS total score ranging from 0-44 is obtained based on 22 items with each item on the 0-2 scale. Lower scores indicate greater dependence on another individual. The SMAIS was completed by participants aged 12 years or older and caregivers of participants aged 2-25 years. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage of Participants Rated by Clinicians as Improved in the Clinical Global Impression of Change (CGI-C) Scale Ratings at Month 12</measure>
    <time_frame>At Month 12</time_frame>
    <description>The Clinical Global Impression of Change (CGI-C) is used to score a clinician's impression of a participant's change in global health. The CGI-C is a single item measure of change in global health, using seven response options: &quot;very much improved&quot;, &quot;much improved&quot;, &quot;minimally improved&quot;, &quot;no change&quot;, &quot;minimally worse&quot;, &quot;much worse&quot;, and &quot;very much worse&quot;. Participants considered as &quot;improved&quot; included responses of &quot;very much improved, &quot;much improved&quot; and &quot;minimally improved&quot;. Logistic regression analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage of Participants Who Achieve Stabilization or Improvement (Defined as &gt;= 0) in the Total Motor Function Measure (MFM-32) Score at Month 12</measure>
    <time_frame>At Month 12</time_frame>
    <description>The MFM32 comprises 32 items that evaluate physical function in three dimensions: D1 function related to standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and &quot;normally&quot;. The 32 scores are summed and expressed on a 0-100 scale for the MFM32 total score. Higher scores indicate increased motor function. Logistic regression analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage of Participants Who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM-32 Score at Month 12</measure>
    <time_frame>At Month 12</time_frame>
    <description>The MFM32 comprises 32 items that evaluate physical function in three dimensions: D1 standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0-cannot initiate the task or maintain the starting position; 1-performs the task partially; 2-performs the task incompletely or imperfectly; 3-performs the task fully and &quot;normally&quot;. The 32 scores are summed and expressed on a 0-100 scale for the total score. Higher scores indicate increased motor function. Standard error of measurement (SEM) is derived using 32 items scores and total scores at baseline. Change from baseline &gt; = one SEM is equivalent to a change &gt;= 4. Logistic regression analysis was performed based on efficacy hypothetical estimand included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change From Baseline in the MFM-32 Domain 1 (D1) Score at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
    <description>The MFM32 comprises 32 items that evaluate physical function in three dimensions: D1 function related to standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and &quot;normally&quot;. The D1 items score are summed and expressed on 0-100 scale for the MFM D1 total score. Higher scores indicate increased motor function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change From Baseline in the MFM-32 Domain 2 (D2) Score at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
    <description>The MFM32 comprises 32 items that evaluate physical function in three dimensions: D1 function related to standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and &quot;normally&quot;. The D2 items score are summed and expressed on 0-100 scale for the MFM D2 total score. Higher scores indicate increased motor function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change From Baseline in the MFM-32 Domain 3 (D3) Score at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
    <description>The MFM32 comprises 32 items that evaluate physical function in three dimensions: D1 function related to standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and &quot;normally&quot;. The D3 items score are summed and expressed on 0-100 scale for the MFM D3 total score. Higher scores indicate increased motor function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change From Baseline in the Total Combined Scores of MFM-32 Domains 1 and 2 at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
    <description>The MFM32 comprises 32 items that evaluate physical function in three dimensions: D1 function related to standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and &quot;normally&quot;. The D1+D2 items score are summed and expressed on 0-100 scale for the MFM D1+D2 total score. Higher scores indicate increased motor function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change From Baseline in the Total Combined Scores of MFM-32 Domains 2 and 3 at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
    <description>The MFM32 comprises 32 items that evaluate physical function in three dimensions: D1 function related to standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and &quot;normally&quot;. The D2+D3 items score are summed and expressed on 0-100 scale for the MFM D2+D3 total score. Higher scores indicate increased motor function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12 in Participants Aged 6-25 Years</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
    <description>Spirometry is a pulmonary function test that assesses how the lungs work by measuring how much air moves through the airways. Spirometry was performed by all participants aged 6 or older. Forced expiratory volume (FEV1) is the volume forcefully exhaled in the first second of the forced vital capacity test. The best % predicted value out of all attempts were used for the analysis. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change From Baseline in the Peak Cough Flow (PCF) at Month 12 in Participants Aged 6-25 Years</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
    <description>Spirometry is a pulmonary function test that assesses how the lungs work by measuring how much air moves through the airways. Spirometry was performed by all participants aged 6 or older. Peak cough flow (PCF) is an assessment of cough strength. The best % predicted value out of all attempts were used for the analysis MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change From Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
    <description>The Sniff Nasal Inspiratory Pressure (SNIP) is a volitional, non-invasive test of inspiratory muscle strength that has been successfully applied to children &gt; 2 years of age. Advantages include the simplicity of the maneuver and the absence of a mouthpiece, which is particularly helpful for participants with SMA, who may have bulbar weakness. SNIP also has the advantage of measuring inspiratory pressure during a natural maneuver that is easily performed even by young children with neuromuscular disorders. The best % predicted value out of all attempts were used for the analysis. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change From Baseline in Maximal Inspiratory Pressure (MIP) at Month 12 in Participants Aged 6-25 Years</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
    <description>The maximal inspiratory pressure (MIP) is a non-invasive test of muscle strength, which measures the maximum strength of the diaphragm and other inspiratory muscles. MIP was measured in participants aged 6 or older. Participants were asked to perform a forceful inspiration against an occluded mouth piece. The best % predicted value out of all attempts were used for the analysis. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change From Baseline in Maximal Expiratory Pressure (MEP) at Month 12 in Participants Aged 6-25 Years</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
    <description>The maximal expiratory pressure (MEP) is a non-invasive test of muscle strength, which measures the maximum strength of the abdominal muscles and other expiratory muscles. MEP was measured in participants aged 6 or older. Participants were asked to perform a forceful inspiration against an occluded mouth piece. The best % predicted value out of all attempts were used for the analysis. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change From Baseline in the Participant-Reported SMA Independence Scale (SMAIS) Total Score at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
    <description>The SMAIS was developed specifically for SMA participants in order to assess function-related independence. It contains 29 items, assessing the amount of assistance required from another individual to perform daily activities such as eating, or bathing. Each item is scored on a 0-4 scale (with an additional option to indicate that an item is non-applicable). The SMAIS total score ranging from 0-44 is obtained based on 22 items with each item on the 0-2 scale. Lower scores indicate greater dependence on another individual. The SMAIS was completed by participants aged 12 years or older and caregivers of participants aged 2-25 years. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage of Participants Rated by Clinicians as No Change or Improved in the Clinical Global Impression of Change (CGI-C) Scale Ratings at Month 12</measure>
    <time_frame>At Month 12</time_frame>
    <description>The CGI-C is used to score a clinician's impression of a participant's change in global health. It is a single item measure of change in global health, using seven response options: &quot;very much improved&quot;, &quot;much improved&quot;, &quot;minimally improved&quot;, &quot;no change&quot;, &quot;minimally worse&quot;, &quot;much worse&quot;, and &quot;very much worse&quot;. Participants considered as &quot;no change or improved&quot; included responses of &quot;no change&quot;, &quot;very much improved&quot;, &quot;much improved&quot; and &quot;minimally improved&quot;. Logistic regression analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage of Participants Who Experience at Least One Disease-Related Adverse Event at Month 12</measure>
    <time_frame>Baseline up to Month 12 (Week 52; up to CCOD of 06 September 2019)</time_frame>
    <description>Disease-related adverse events (AEs) were identified by applying two different types of baskets to the AE dataset: Narrow prospectively defined baskets of MedDRA lowest level terms. This basket was defined based on a group of CDC terms selected from an age and gender matched case control study comparing CDC code rates observed in participants with and without SMA using commercially available insurance claim data (CLAIMS and Market scan data). The lowest level terms included in each basket, coded using the latest version of MedDRA; Broad prospectively defined basket with events selected at preferred term level from all AEs reported in ongoing clinical trials up to January 2019, i.e., prior to unblinding of Part 2 of Study BP39055.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of Disease-related Adverse Events Per Patient-years at Month 12</measure>
    <time_frame>Baseline up to Month 12 (Week 52; up to CCOD of 06 September 2019)</time_frame>
    <description>Disease-related AEs were collected through the AE reporting of the study, and the disease-related AE rate was adjusted for patient years (AE rate per 100 patient-years). They were identified by applying two different types of baskets to the AE dataset: Narrow prospectively defined baskets of MedDRA lowest level terms and Broad prospectively defined basket with events selected at preferred term level from all AEs reported in ongoing clinical trials up to January 2019, i.e., prior to unblinding of Part 2 of Study BP39055.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 1 on risdiplam up to end of study (up to approximately 7 years)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) in the Placebo-Controlled Period</measure>
    <time_frame>Day 1 up to 12 months of the placebo-controlled period</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage of Participants With Treatment Discontinuation Due to Adverse Events (AEs) and Serious Adverse Events (SAEs) in the Placebo-Controlled Period</measure>
    <time_frame>Day 1 up to 12 months of the placebo-controlled period</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of Participants Aged 6-25 Years With Suicidal Ideation Based on Columbia-Suicide Severity Rating Scale (C-SSRS) in the Placebo-Controlled Period</measure>
    <time_frame>Day 1 up to 12 months of the placebo-controlled period</time_frame>
    <description>The Columbia Suicide Severity Rating Scale (C-SSRS) is used to assess the lifetime suicidality of a participant (C-SSRS baseline) as well as any new instances of suicidality (C-SSRS since last visit). The structured interview prompts recollection of suicidal ideation, including the intensity of the ideation, behavior, and attempts with actual/potential lethality. The C-SSRS assessments results were collected for participants aged 6 years and older.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of Participants Aged 6-25 Years With Suicidal Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) in the Placebo-Controlled Period</measure>
    <time_frame>Day 1 up to 12 months of the placebo-controlled period</time_frame>
    <description>The Columbia Suicide Severity Rating Scale (C-SSRS) is used to assess the lifetime suicidality of a participant (C-SSRS baseline) as well as any new instances of suicidality (C-SSRS since last visit). The structured interview prompts recollection of suicidal ideation, including the intensity of the ideation, behavior, and attempts with actual/potential lethality. The C-SSRS assessments results were collected for participants aged 6 years and older.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood</measure>
    <time_frame>Part 2: Days -1, 1, 7, 28, 120, 246, 365, 729</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival of Motor Neuron (SMN) Protein Levels in Blood</measure>
    <time_frame>Part 2: Days -1, 7, 28, 120, 246, 365, 729</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam</measure>
    <time_frame>Part 1 and 2: 1, 2, 4, 6 hours post dose on Day 1; Pre-dose (Hour 0) on Days 7, 14, 56 (Part 2), 120, 246, 490, 729; pre-dose (Hour 0) and 1, 2, 4, 6 hours post dose on Days 28, 56 (Part 1), 365, 609</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Area Under the Curve (AUC) of Risdiplam</measure>
    <time_frame>Part 1 and 2: 1, 2, 4, 6 hours post dose on Day 1; Pre-dose (Hour 0) on Days 7, 14, 56 (Part 2), 120, 246, 490, 729; pre-dose (Hour 0) and 1, 2, 4, 6 hours post dose on Days 28, 56 (Part 1), 365, 609</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam</measure>
    <time_frame>Part 1 and 2: Pre-dose (Hour 0) on Days 7, 14, 28, 56, 120, 246, 365, 490, 609, 729</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">231</enrollment>
  <condition>Muscular Atrophy, Spinal</condition>
  <arm_group>
    <arm_group_label>Part 1 Group A: Adolescents and Adults (Risdiplam)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adolescent and adult participants aged 12-25 years will receive risdiplam for at least 12 weeks. Once the placebo-controlled period is completed and Part 2 dose is selected, participants will be switched to Part 2 dose and will be treated in an open-label phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Group A: Adolescents and Adults (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Adolescent and adult participants aged 12-25 years will receive placebo matching to risdiplam for at least 12 weeks. Once placebo-controlled period is completed, participants will be first switched to their cohort risdiplam dose. After the Part 2 dose is selected, participants will be switched to Part 2 dose and will be treated in an open-label phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Group B: Children (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Children aged 2-11 years will receive placebo matching to risdiplam for at least 12 weeks. Once placebo-controlled period is completed, participants will be first switched to their cohort risdiplam dose. After the Part 2 dose is selected, participants will be switched to Part 2 dose and will be treated in an open-label phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Group B: Children (Risdiplam)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children aged 2-11 years will receive risdiplam for at least 12 weeks. Once the placebo-controlled period is completed and Part 2 dose is selected, participants will be switched to Part 2 dose and will be treated in an open-label phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants aged 2-25 years will receive placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants will be switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment until Month 24. After Month 24, participants will be offered the opportunity to enter the open-label phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Risdiplam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 2-25 years will receive risdiplam at the dose selected based on the results from Part 1 of the study (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg), for 24 months. After 24-month treatment, participants will be offered the opportunity to enter the open-label phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).</description>
    <arm_group_label>Part 1 Group A: Adolescents and Adults (Placebo)</arm_group_label>
    <arm_group_label>Part 1 Group B: Children (Placebo)</arm_group_label>
    <arm_group_label>Part 2: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risdiplam</intervention_name>
    <description>Risdiplam will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).</description>
    <arm_group_label>Part 1 Group A: Adolescents and Adults (Placebo)</arm_group_label>
    <arm_group_label>Part 1 Group A: Adolescents and Adults (Risdiplam)</arm_group_label>
    <arm_group_label>Part 1 Group B: Children (Placebo)</arm_group_label>
    <arm_group_label>Part 1 Group B: Children (Risdiplam)</arm_group_label>
    <arm_group_label>Part 2: Placebo</arm_group_label>
    <arm_group_label>Part 2: Risdiplam</arm_group_label>
    <other_name>RO7034067</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of 5q-autosomal recessive SMA&#xD;
&#xD;
          -  Negative blood pregnancy test at screening and agreement to comply with measures to&#xD;
             prevent pregnancy and restrictions on sperm donation&#xD;
&#xD;
          -  For Part 1: Type 2 or 3 SMA ambulant or non-ambulant&#xD;
&#xD;
          -  For Part 2: 1) Type 2 or 3 SMA non-ambulant; 2) RULM entry item A greater than or&#xD;
             equal to 2; 3) ability to sit independently as assessed by item 9 of the MFM&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant or previous participation in any investigational drug or device study&#xD;
             within 90 days prior to screening, or 5 half-lives of the drug, whichever is longer&#xD;
&#xD;
          -  Concomitant or previous administration of a SMN2-targeting antisense oligonucleotide,&#xD;
             SMN2 splicing modifier or gene therapy either in a clinical study or as part of&#xD;
             medical care&#xD;
&#xD;
          -  Any history of cell therapy&#xD;
&#xD;
          -  Hospitalization for a pulmonary event within the last 2 months or planned at time of&#xD;
             screening&#xD;
&#xD;
          -  Surgery for scoliosis or hip fixation in the one year preceding screening or planned&#xD;
             within the next 18 months&#xD;
&#xD;
          -  Unstable gastrointestinal, renal, hepatic, endocrine, or cardiovascular system&#xD;
             diseases as considered to be clinically significant by the Investigator&#xD;
&#xD;
          -  Presence of clinically significant electrocardiogram abnormalities before study drug&#xD;
             administration from average of triplicate measurement or cardiovascular disease&#xD;
             indicating a safety risk for participants as determined by the Investigator&#xD;
&#xD;
          -  Any major illness within one month before the screening examination or any febrile&#xD;
             illness within one week prior to screening and up to first dose administration&#xD;
&#xD;
          -  Recently initiated treatment (within less than [&lt;] 6 months prior to randomization)&#xD;
             with oral salbutamol or another beta 2-adrenergic agonist taken orally&#xD;
&#xD;
          -  Any prior use of chloroquine, hydroxychloroquine, retigabin, vigabatrin or&#xD;
             thioridazine, is not allowed&#xD;
&#xD;
          -  Ascertained or presumptive hypersensitivity (e.g., anaphylactic reaction) to Risdiplam&#xD;
             or to the constituents of its formulation&#xD;
&#xD;
          -  Recent history (less than one year) of ophthalmological diseases&#xD;
&#xD;
          -  Participants requiring invasive ventilation or tracheostomy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center; The Neurological Institute of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chr de La Citadelle</name>
      <address>
        <city>Liege</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Puericultura E Pediatria Martagão Gesteira</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>CEP 21941-912</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital Division of Pediatric Neurology</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre; Children's Hospital; Pediatrics</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre - Glen Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing City</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>201102</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Medical Center Zagreb; University Hospital Rebro Department of Paediatrics</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Femme Mere Enfant; Medecine Physique et Readaptation Pediatrique - L'ESCALE</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants Malades; Service de neuropédiatrie</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Armand Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg; Klinik für Neuropädiatrie und Muskelerkrankungen</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Pediatrico Bambino Gesù; U.O. Malattie Neuromuscolari e Neurodegenerative</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Agostino Gemelli; Dipartimento di Neuropsichiatria Infantile</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Giannina Gaslini; U.O.S.D. Centro di Miologia e Patologie Neurodegenerative</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Unità Operativa Complessa di Neurologia</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Neurologico &quot;Carlo Besta&quot;; UO di Neurologia dello Sviluppo</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka Children's Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>813-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine Hospital</name>
      <address>
        <city>Hyogo</city>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minami Kyushu National Hospital</name>
      <address>
        <city>Kagoshima</city>
        <zip>899-5293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyagi Children's Hospital</name>
      <address>
        <city>Miyagi</city>
        <zip>989-3126</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shiga Medical Center for Children</name>
      <address>
        <city>Shiga</city>
        <zip>524-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Children's Hospital</name>
      <address>
        <city>Shizuoka</city>
        <zip>420-8660</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University Hospital</name>
      <address>
        <city>Tochigi</city>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center Hospital of the National Center for Global Health and Medicine</name>
      <address>
        <city>Tokyo</city>
        <zip>162-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Center Of Neurology And Psychiatry Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>187-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Gdanskiego Uniwersytetu Medycznego; Clinic of developmental neurology</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny im. H. Swiecickiego U.M. w Poznaniu; Od. Kliniczny Neurologii Dzieci i Młodziezy</name>
      <address>
        <city>Poznań</city>
        <zip>60-355</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Neurologii I Wydzialu Lekarskiego WUM w Warszawie</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Children Neuromuscular Center of Veltischev</name>
      <address>
        <city>Moscow</city>
        <state>Moskovskaja Oblast</state>
        <zip>125412</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic for Neurology and Psychiatry for Children and Youth</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan De Deu</name>
      <address>
        <city>Esplugues De Llobregas</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron; Servicio de Reumatologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>280146</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío; Servicio de Neuropediatra</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe University, School of Medicine; Pediatrics Department; Pediatrics Child Neurology Unit</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Yeditepe University Kozyatagi; Pediatry</name>
      <address>
        <city>Atasehir- Istanbul</city>
        <zip>34752</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oxford; Department of Paediatrics</name>
      <address>
        <city>Headington</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Croatia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
  </removed_countries>
  <link>
    <url>http://roche-sma-clinicaltrials.com</url>
    <description>roche-sma-clinicaltrials.com provides information about the Roche Sunfish clinical trial NCT02908685 and molecule being investigated in SMA.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 19, 2016</study_first_submitted>
  <study_first_submitted_qc>September 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <results_first_submitted>August 27, 2020</results_first_submitted>
  <results_first_submitted_qc>May 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 15, 2021</results_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risdiplam</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 22, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT02908685/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 21, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT02908685/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study Part 1 was conducted at 5 investigational sites across 4 countries, and Part 2 was conducted at 42 investigational sites across 14 countries. The Screening in both Part 1 and 2 was up to 30 days prior to first dose.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1 Group A Cohort 1: Adolescents and Adults (3 mg Risdiplam)</title>
          <description>Adolescent and adult participants aged 12-25 years received risdiplam for at least 12 weeks. Once the placebo-controlled period was completed and Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.</description>
        </group>
        <group group_id="P2">
          <title>Part 1 Group A Cohort 2: Adolescents and Adults (5 mg Risdiplam)</title>
          <description>Adolescent and adult participants aged 12-25 years received risdiplam for at least 12 weeks. Once the placebo-controlled period was completed and Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.</description>
        </group>
        <group group_id="P3">
          <title>Part 1 Group A Cohort 1: Adolescents and Adults (Placebo)</title>
          <description>Adolescent and adult participants aged 12-25 years received placebo matching to risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, participants first switched to their cohort risdiplam dose (i.e. 3 mg). After the Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.</description>
        </group>
        <group group_id="P4">
          <title>Part 1 Group A Cohort 2: Adolescents and Adults (Placebo)</title>
          <description>Adolescent and adult participants aged 12-25 years received placebo matching to risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, participants first switched to their cohort risdiplam dose (i.e. 5 mg). After the Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.</description>
        </group>
        <group group_id="P5">
          <title>Part 1 Group B Cohort 1: Children (0.02 mg/kg Risdiplam)</title>
          <description>Children aged 2-11 years received risdiplam for at least 12 weeks. During the placebo-controlled period, participants escalated to 0.05 mg/kg and then to 0.15 mg/kg in two steps. Once the placebo-controlled period was completed, and after Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.</description>
        </group>
        <group group_id="P6">
          <title>Part 1 Group B Cohort 2: Children (0.05 mg/kg Risdiplam)</title>
          <description>Children aged 2-11 years received risdiplam for at least 12 weeks. During the placebo-controlled period, participants escalated to 0.15 mg/kg in one step. Once the placebo-controlled period was completed, and after Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.</description>
        </group>
        <group group_id="P7">
          <title>Part 1 Group B Cohort 3: Children (0.25 mg/kg Risdiplam)</title>
          <description>Children aged 2-11 years received risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, and after Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.</description>
        </group>
        <group group_id="P8">
          <title>Part 1 Group B Cohort 1: Children (Placebo)</title>
          <description>Children aged 2-11 years received placebo matching to risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, participants first switched to the final 0.15 mg/kg cohort risdiplam dose. After the Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.</description>
        </group>
        <group group_id="P9">
          <title>Part 1 Group B Cohort 2: Children (Placebo)</title>
          <description>Children aged 2-11 years received placebo matching to risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, participants first switched to the final 0.15 mg/kg cohort risdiplam dose. After the Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.</description>
        </group>
        <group group_id="P10">
          <title>Part 1 Group B Cohort 3: Children (Placebo)</title>
          <description>Children aged 2-11 years received placebo matching to risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, and after Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.</description>
        </group>
        <group group_id="P11">
          <title>Part 2: Risdiplam</title>
          <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
        </group>
        <group group_id="P12">
          <title>Part 2: Placebo</title>
          <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1 Exploratory</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 2 Confirmatory</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="120"/>
                <participants group_id="P12" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="117"/>
                <participants group_id="P12" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Changed to Spinraza</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Changed to other treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part 1 Group A Cohort 1: Adolescents and Adults (3 mg Risdiplam)</title>
          <description>Adolescent and adult participants aged 12-25 years received risdiplam for at least 12 weeks. Once the placebo-controlled period was completed and Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.</description>
        </group>
        <group group_id="B2">
          <title>Part 1 Group A Cohort 2: Adolescents and Adults (5 mg Risdiplam)</title>
          <description>Adolescent and adult participants aged 12-25 years received risdiplam for at least 12 weeks. Once the placebo-controlled period was completed and Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.</description>
        </group>
        <group group_id="B3">
          <title>Part 1 Group A Cohort 1: Adolescents and Adults (Placebo)</title>
          <description>Adolescent and adult participants aged 12-25 years received placebo matching to risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, participants first switched to their cohort risdiplam dose (i.e. 3 mg). After the Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.</description>
        </group>
        <group group_id="B4">
          <title>Part 1 Group A Cohort 2: Adolescents and Adults (Placebo)</title>
          <description>Adolescent and adult participants aged 12-25 years received placebo matching to risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, participants first switched to their cohort risdiplam dose (i.e. 5 mg). After the Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.</description>
        </group>
        <group group_id="B5">
          <title>Part 1 Group B Cohort 1: Children (0.02 mg/kg Risdiplam)</title>
          <description>Children aged 2-11 years received risdiplam for at least 12 weeks. During the placebo-controlled period, participants escalated to 0.05 mg/kg and then to 0.15 mg/kg in two steps. Once the placebo-controlled period was completed, and after Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.</description>
        </group>
        <group group_id="B6">
          <title>Part 1 Group B Cohort 2: Children (0.05 mg/kg Risdiplam)</title>
          <description>Children aged 2-11 years received risdiplam for at least 12 weeks. During the placebo-controlled period, participants escalated to 0.15 mg/kg in one step. Once the placebo-controlled period was completed, and after Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.</description>
        </group>
        <group group_id="B7">
          <title>Part 1 Group B Cohort 3: Children (0.25 mg/kg Risdiplam)</title>
          <description>Children aged 2-11 years received risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, and after Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.</description>
        </group>
        <group group_id="B8">
          <title>Part 1 Group B Cohort 1: Children (Placebo)</title>
          <description>Children aged 2-11 years received placebo matching to risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, participants first switched to the final 0.15 mg/kg cohort risdiplam dose. After the Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.</description>
        </group>
        <group group_id="B9">
          <title>Part 1 Group B Cohort 2: Children (Placebo)</title>
          <description>Children aged 2-11 years received placebo matching to risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, participants first switched to the final 0.15 mg/kg cohort risdiplam dose. After the Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.</description>
        </group>
        <group group_id="B10">
          <title>Part 1 Group B Cohort 3: Children (Placebo)</title>
          <description>Children aged 2-11 years received placebo matching to risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, and after Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.</description>
        </group>
        <group group_id="B11">
          <title>Part 2: Risdiplam</title>
          <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
        </group>
        <group group_id="B12">
          <title>Part 2: Placebo</title>
          <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
        </group>
        <group group_id="B13">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="7"/>
            <count group_id="B6" value="7"/>
            <count group_id="B7" value="7"/>
            <count group_id="B8" value="3"/>
            <count group_id="B9" value="4"/>
            <count group_id="B10" value="3"/>
            <count group_id="B11" value="120"/>
            <count group_id="B12" value="60"/>
            <count group_id="B13" value="231"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Intent-to-Treat (ITT) population: Part 1 and Part 2 were analyzed separately and population results are provided for each part in the study.</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Part 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="3"/>
                    <count group_id="B4" value="3"/>
                    <count group_id="B5" value="7"/>
                    <count group_id="B6" value="7"/>
                    <count group_id="B7" value="7"/>
                    <count group_id="B8" value="3"/>
                    <count group_id="B9" value="4"/>
                    <count group_id="B10" value="3"/>
                    <count group_id="B11" value="0"/>
                    <count group_id="B12" value="0"/>
                    <count group_id="B13" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.3" spread="1.1"/>
                    <measurement group_id="B2" value="18.1" spread="4.6"/>
                    <measurement group_id="B3" value="14.7" spread="1.5"/>
                    <measurement group_id="B4" value="17.3" spread="5.1"/>
                    <measurement group_id="B5" value="6.1" spread="2.9"/>
                    <measurement group_id="B6" value="4.3" spread="1.7"/>
                    <measurement group_id="B7" value="6.0" spread="2.7"/>
                    <measurement group_id="B8" value="5.3" spread="2.1"/>
                    <measurement group_id="B9" value="3.5" spread="0.6"/>
                    <measurement group_id="B10" value="5.3" spread="2.9"/>
                    <measurement group_id="B13" value="9.4" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="120"/>
                    <count group_id="B12" value="60"/>
                    <count group_id="B13" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B11" value="9.9" spread="5.8"/>
                    <measurement group_id="B12" value="10.3" spread="6.0"/>
                    <measurement group_id="B13" value="10.0" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="3"/>
                    <count group_id="B4" value="3"/>
                    <count group_id="B5" value="7"/>
                    <count group_id="B6" value="7"/>
                    <count group_id="B7" value="7"/>
                    <count group_id="B8" value="3"/>
                    <count group_id="B9" value="4"/>
                    <count group_id="B10" value="3"/>
                    <count group_id="B11" value="120"/>
                    <count group_id="B12" value="60"/>
                    <count group_id="B13" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="61"/>
                    <measurement group_id="B12" value="30"/>
                    <measurement group_id="B13" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="59"/>
                    <measurement group_id="B12" value="30"/>
                    <measurement group_id="B13" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="3"/>
                    <count group_id="B4" value="3"/>
                    <count group_id="B5" value="7"/>
                    <count group_id="B6" value="7"/>
                    <count group_id="B7" value="7"/>
                    <count group_id="B8" value="3"/>
                    <count group_id="B9" value="4"/>
                    <count group_id="B10" value="3"/>
                    <count group_id="B11" value="120"/>
                    <count group_id="B12" value="60"/>
                    <count group_id="B13" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="23"/>
                    <measurement group_id="B12" value="12"/>
                    <measurement group_id="B13" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="80"/>
                    <measurement group_id="B12" value="41"/>
                    <measurement group_id="B13" value="169"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multiple</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="14"/>
                    <measurement group_id="B12" value="7"/>
                    <measurement group_id="B13" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="3"/>
                    <count group_id="B4" value="3"/>
                    <count group_id="B5" value="7"/>
                    <count group_id="B6" value="7"/>
                    <count group_id="B7" value="7"/>
                    <count group_id="B8" value="3"/>
                    <count group_id="B9" value="4"/>
                    <count group_id="B10" value="3"/>
                    <count group_id="B11" value="120"/>
                    <count group_id="B12" value="60"/>
                    <count group_id="B13" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="114"/>
                    <measurement group_id="B12" value="57"/>
                    <measurement group_id="B13" value="221"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Stated</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Selected Part 2 Dose of Risdiplam for Participants With a Body Weight (BW) of &gt;/=20kg</title>
        <description>The Internal Monitoring Committee (IMC) was responsible for selecting the dose for Part 2 of the study (pivotal dose). An external Independent Data Monitoring Committee (iDMC) reviewed data from Part 1 and confirmed the dose-selection decision of the IMC. The dose for Part 2 selected by the IMC was a dose that: 1.Was judged to be safe and well-tolerated, based on all available safety data from Part 1 and as confirmed by the iDMC; 2. Resulted in an exposure at steady-state below the exposure cap (mean value) of AUC0-24h,ss 2000 ng*h/mL (adjusted for free-fraction, if required); 3. Resulted in an SMN protein increase that was expected to be clinically relevant.</description>
        <time_frame>Day 1 up to at least 4 weeks on study (Up to CCOD of 25 July 2017)</time_frame>
        <population>All participants in Part 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: All Risdiplam</title>
            <description>Children aged 2-11 years and adolescent and adult participants aged 12-25 years received risdiplam or risdiplam matching placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Selected Part 2 Dose of Risdiplam for Participants With a Body Weight (BW) of &gt;/=20kg</title>
          <description>The Internal Monitoring Committee (IMC) was responsible for selecting the dose for Part 2 of the study (pivotal dose). An external Independent Data Monitoring Committee (iDMC) reviewed data from Part 1 and confirmed the dose-selection decision of the IMC. The dose for Part 2 selected by the IMC was a dose that: 1.Was judged to be safe and well-tolerated, based on all available safety data from Part 1 and as confirmed by the iDMC; 2. Resulted in an exposure at steady-state below the exposure cap (mean value) of AUC0-24h,ss 2000 ng*h/mL (adjusted for free-fraction, if required); 3. Resulted in an SMN protein increase that was expected to be clinically relevant.</description>
          <population>All participants in Part 1.</population>
          <units>milligram (mg)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Selected Part 2 Dose of Risdiplam for Participants With BW of &lt;20kg</title>
        <description>The Internal Monitoring Committee (IMC) was responsible for selecting the dose for Part 2 of the study (pivotal dose). An external Independent Data Monitoring Committee (iDMC) reviewed data from Part 1 and confirmed the dose-selection decision of the IMC. The dose for Part 2 selected by the IMC was a dose that: 1.Was judged to be safe and well-tolerated, based on all available safety data from Part 1 and as confirmed by the iDMC; 2. Resulted in an exposure at steady-state below the exposure cap (mean value) of AUC0-24h,ss 2000 ng*h/mL (adjusted for free-fraction, if required); 3. Resulted in an SMN protein increase that was expected to be clinically relevant.</description>
        <time_frame>Day 1 up to at least 4 weeks on study (Up to CCOD of 25 July 2017)</time_frame>
        <population>All participants in Part 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: All Risdiplam</title>
            <description>Children aged 2-11 years and adolescent and adult participants aged 12-25 years received risdiplam or risdiplam matching placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Selected Part 2 Dose of Risdiplam for Participants With BW of &lt;20kg</title>
          <description>The Internal Monitoring Committee (IMC) was responsible for selecting the dose for Part 2 of the study (pivotal dose). An external Independent Data Monitoring Committee (iDMC) reviewed data from Part 1 and confirmed the dose-selection decision of the IMC. The dose for Part 2 selected by the IMC was a dose that: 1.Was judged to be safe and well-tolerated, based on all available safety data from Part 1 and as confirmed by the iDMC; 2. Resulted in an exposure at steady-state below the exposure cap (mean value) of AUC0-24h,ss 2000 ng*h/mL (adjusted for free-fraction, if required); 3. Resulted in an SMN protein increase that was expected to be clinically relevant.</description>
          <population>All participants in Part 1.</population>
          <units>milligram/kilogram (mg/kg)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Change From Baseline in the Total Motor Function Measure 32 (MFM-32) Total Score at Month 12</title>
        <description>The Motor Function Measure 32 (MFM32) is a scale constructed for use in neuromuscular disorders. It comprises 32 items that evaluate physical function in three dimensions: D1 function related to standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and &quot;normally&quot;. The 32 scores are summed and expressed on a 0-100 scale for the MFM32 total score. Higher scores indicate increased motor function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on primary efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
        <time_frame>Baseline (Day-1) and Month 12</time_frame>
        <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing MFM32 total score at Baseline were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Risdiplam</title>
            <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Change From Baseline in the Total Motor Function Measure 32 (MFM-32) Total Score at Month 12</title>
          <description>The Motor Function Measure 32 (MFM32) is a scale constructed for use in neuromuscular disorders. It comprises 32 items that evaluate physical function in three dimensions: D1 function related to standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and &quot;normally&quot;. The 32 scores are summed and expressed on a 0-100 scale for the MFM32 total score. Higher scores indicate increased motor function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on primary efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
          <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing MFM32 total score at Baseline were not included in the analysis.</population>
          <units>Scores on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" lower_limit="0.61" upper_limit="2.11"/>
                    <measurement group_id="O2" value="-0.19" lower_limit="-1.22" upper_limit="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This is the first end point and first family tested in the hierarchical testing. The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.</non_inferiority_desc>
            <p_value>0.0156</p_value>
            <method>Mixed Model Repeated Measure Analysis</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>1.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>2.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Percentage of Participants With Marked Improvement (Defined as &gt;= 3) in the Total Motor Function Measure (MFM32) Score at Month 12</title>
        <description>The MFM32 comprises 32 items that evaluate physical function. The scoring of each task uses a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and &quot;normally&quot;. The 32 scores are summed and expressed on a 0-100 scale for the MFM32 total score. A change in MFM32 total score of threshold &gt;/=3 represents marked improvement in this measure. Logistic regression analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
        <time_frame>At Month 12</time_frame>
        <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing MFM32 total score at Baseline were not included in the analysis. Missing results at Month 12 are considered as non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Risdiplam</title>
            <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percentage of Participants With Marked Improvement (Defined as &gt;= 3) in the Total Motor Function Measure (MFM32) Score at Month 12</title>
          <description>The MFM32 comprises 32 items that evaluate physical function. The scoring of each task uses a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and &quot;normally&quot;. The 32 scores are summed and expressed on a 0-100 scale for the MFM32 total score. A change in MFM32 total score of threshold &gt;/=3 represents marked improvement in this measure. Logistic regression analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
          <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing MFM32 total score at Baseline were not included in the analysis. Missing results at Month 12 are considered as non-responders.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3" lower_limit="28.94" upper_limit="47.58"/>
                    <measurement group_id="O2" value="23.7" lower_limit="12.03" upper_limit="35.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This is the second end point and second family tested in the hierarchical testing. Logistic Regression Model.The variables included in the logistic regression are: baseline total score, treatment and age group.</non_inferiority_desc>
            <p_value>0.0469</p_value>
            <p_value_desc>Adjusted p-Value The adjusted p-values were derived based on all the p-values from end points in order of the hierarchical testing up to the current endpoint.</p_value_desc>
            <method>Wald test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>5.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Change From Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12</title>
        <description>The RULM is a 20 items scale that assesses the proximal and distal motor functions of the arm. There is an entry item and the remaining 18 items are scored on the 3 point scale of: 0: cannot complete task independently; 1: modified method but can complete task independently; 2: completes task without any assistance, and with 1 item scored on a 2 point scale of as a can/cannot score with 1 as the highest score. The RULM total score is the sum of 19 items scores with range of 0-37, and the entry item does not contribute to the total score. Higher scores indicate greater upper limb function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on the efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
        <time_frame>Baseline (Day-1) and Month 12</time_frame>
        <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing RULM total score at Baseline were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Risdiplam</title>
            <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Change From Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12</title>
          <description>The RULM is a 20 items scale that assesses the proximal and distal motor functions of the arm. There is an entry item and the remaining 18 items are scored on the 3 point scale of: 0: cannot complete task independently; 1: modified method but can complete task independently; 2: completes task without any assistance, and with 1 item scored on a 2 point scale of as a can/cannot score with 1 as the highest score. The RULM total score is the sum of 19 items scores with range of 0-37, and the entry item does not contribute to the total score. Higher scores indicate greater upper limb function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on the efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
          <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing RULM total score at Baseline were not included in the analysis.</population>
          <units>Scores on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" lower_limit="1.00" upper_limit="2.22"/>
                    <measurement group_id="O2" value="0.02" lower_limit="-0.83" upper_limit="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This is the third end point and third family tested in the hierarchical testing. The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.</non_inferiority_desc>
            <p_value>0.0469</p_value>
            <p_value_desc>Adjusted p-Value The adjusted p-values were derived based on all the p-values from end points in order of the hierarchical testing up to the current endpoint.</p_value_desc>
            <method>Mixed Model Repeated Measure Analysis</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>1.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>2.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Change From Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12</title>
        <description>The HFMSE scale contains 33 items, which are scored on a 3-point Likert-type scale (0-2) and summed to derive the total score, with lower scores indicating greater impairment. The HFMSE contains a series of assessments designed to assess important functional abilities, including standing, transfers, ambulation, and proximal and axial function. The overall score is the sum of the scores for all activities with a maximum achievable score of 66. Higher scores indicate greater motor function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on the efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
        <time_frame>Baseline (Day-1) and Month 12</time_frame>
        <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Risdiplam</title>
            <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Change From Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12</title>
          <description>The HFMSE scale contains 33 items, which are scored on a 3-point Likert-type scale (0-2) and summed to derive the total score, with lower scores indicating greater impairment. The HFMSE contains a series of assessments designed to assess important functional abilities, including standing, transfers, ambulation, and proximal and axial function. The overall score is the sum of the scores for all activities with a maximum achievable score of 66. Higher scores indicate greater motor function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on the efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
          <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2.</population>
          <units>Scores on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" lower_limit="0.29" upper_limit="1.61"/>
                    <measurement group_id="O2" value="0.37" lower_limit="-0.54" upper_limit="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This is one of the two end points in family four in the hierarchical testing. The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.</non_inferiority_desc>
            <p_value>0.3902</p_value>
            <p_value_desc>Adjusted p-Value The adjusted p-values were derived based on all the p-values from end points in order of the hierarchical testing up to the current endpoint.</p_value_desc>
            <method>Mixed Model Repeated Measure Analysis</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.53</ci_lower_limit>
            <ci_upper_limit>1.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Change From Baseline in Forced Vital Capacity (FVC) at Month 12 in Participants Aged 6-25 Years</title>
        <description>Spirometry is a pulmonary function test that assesses how the lungs work by measuring how much air moves through the airways. Spirometry was performed by all participants aged 6 or older. Forced vital capacity (FVC) is the total volume that can be exhaled after inhaling maximally. The best % predicted value out of all attempts were used for the analysis. MMRM analysis was performed based on the efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
        <time_frame>Baseline (Day-1) and Month 12</time_frame>
        <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing FVC data at Baseline were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Risdiplam</title>
            <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Change From Baseline in Forced Vital Capacity (FVC) at Month 12 in Participants Aged 6-25 Years</title>
          <description>Spirometry is a pulmonary function test that assesses how the lungs work by measuring how much air moves through the airways. Spirometry was performed by all participants aged 6 or older. Forced vital capacity (FVC) is the total volume that can be exhaled after inhaling maximally. The best % predicted value out of all attempts were used for the analysis. MMRM analysis was performed based on the efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
          <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing FVC data at Baseline were not included in the analysis.</population>
          <units>Percentage Predicted</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.16" lower_limit="-7.93" upper_limit="-2.39"/>
                    <measurement group_id="O2" value="-3.11" lower_limit="-6.59" upper_limit="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This is one of the two end points in family four in the hierarchical testing. The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.</non_inferiority_desc>
            <p_value>0.3902</p_value>
            <p_value_desc>Adjusted p-Value The adjusted p-values were derived based on all the p-values from end points in order of the hierarchical testing up to the current endpoint.</p_value_desc>
            <method>Mixed Model Repeated Measure Analysis</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-2.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.67</ci_lower_limit>
            <ci_upper_limit>2.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Change From Baseline in the Caregiver-Reported SMA Independence Scale (SMAIS) Total Score at Month 12</title>
        <description>The SMA Independence Scale (SMAIS) was developed specifically for SMA participants in order to assess function-related independence. The SMAIS contains 29 items, assessing the amount of assistance required from another individual to perform daily activities such as eating, or bathing. Each item is scored on a 0-4 scale (with an additional option to indicate that an item is non-applicable). The SMAIS total score ranging from 0-44 is obtained based on 22 items with each item on the 0-2 scale. Lower scores indicate greater dependence on another individual. The SMAIS was completed by participants aged 12 years or older and caregivers of participants aged 2-25 years. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
        <time_frame>Baseline (Day-1) and Month 12</time_frame>
        <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing SMAIS total score at Baseline were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Risdiplam</title>
            <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Change From Baseline in the Caregiver-Reported SMA Independence Scale (SMAIS) Total Score at Month 12</title>
          <description>The SMA Independence Scale (SMAIS) was developed specifically for SMA participants in order to assess function-related independence. The SMAIS contains 29 items, assessing the amount of assistance required from another individual to perform daily activities such as eating, or bathing. Each item is scored on a 0-4 scale (with an additional option to indicate that an item is non-applicable). The SMAIS total score ranging from 0-44 is obtained based on 22 items with each item on the 0-2 scale. Lower scores indicate greater dependence on another individual. The SMAIS was completed by participants aged 12 years or older and caregivers of participants aged 2-25 years. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
          <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing SMAIS total score at Baseline were not included in the analysis.</population>
          <units>Scores on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" lower_limit="0.66" upper_limit="2.63"/>
                    <measurement group_id="O2" value="-0.91" lower_limit="-2.23" upper_limit="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This is the sixth endpoint and the fifth family tested in the hierarchical testing. The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.</non_inferiority_desc>
            <p_value>0.3902</p_value>
            <p_value_desc>Adjusted p-Value The adjusted p-values were derived based on all the p-values from end points in order of the hierarchical testing up to the current endpoint.</p_value_desc>
            <method>Mixed Model Repeated Measure Analysis</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>2.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>4.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Percentage of Participants Rated by Clinicians as Improved in the Clinical Global Impression of Change (CGI-C) Scale Ratings at Month 12</title>
        <description>The Clinical Global Impression of Change (CGI-C) is used to score a clinician's impression of a participant's change in global health. The CGI-C is a single item measure of change in global health, using seven response options: &quot;very much improved&quot;, &quot;much improved&quot;, &quot;minimally improved&quot;, &quot;no change&quot;, &quot;minimally worse&quot;, &quot;much worse&quot;, and &quot;very much worse&quot;. Participants considered as &quot;improved&quot; included responses of &quot;very much improved, &quot;much improved&quot; and &quot;minimally improved&quot;. Logistic regression analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
        <time_frame>At Month 12</time_frame>
        <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Missing results at Month 12 are considered as non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Risdiplam</title>
            <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percentage of Participants Rated by Clinicians as Improved in the Clinical Global Impression of Change (CGI-C) Scale Ratings at Month 12</title>
          <description>The Clinical Global Impression of Change (CGI-C) is used to score a clinician's impression of a participant's change in global health. The CGI-C is a single item measure of change in global health, using seven response options: &quot;very much improved&quot;, &quot;much improved&quot;, &quot;minimally improved&quot;, &quot;no change&quot;, &quot;minimally worse&quot;, &quot;much worse&quot;, and &quot;very much worse&quot;. Participants considered as &quot;improved&quot; included responses of &quot;very much improved, &quot;much improved&quot; and &quot;minimally improved&quot;. Logistic regression analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
          <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Missing results at Month 12 are considered as non-responders.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.5" lower_limit="38.15" upper_limit="56.86"/>
                    <measurement group_id="O2" value="40.0" lower_limit="26.77" upper_limit="53.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CGI Improved</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This is the seventh endpoint and the sixth family tested in the hierarchical testing. Logistic Regression Model. The variables included in the logistic regression are: baseline total score, treatment and age group.</non_inferiority_desc>
            <p_value>0.3902</p_value>
            <p_value_desc>Adjusted p-Value The adjusted p-values were derived based on all the p-values from end points in order of the hierarchical testing up to the current endpoint.</p_value_desc>
            <method>Wald-test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>2.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Percentage of Participants Who Achieve Stabilization or Improvement (Defined as &gt;= 0) in the Total Motor Function Measure (MFM-32) Score at Month 12</title>
        <description>The MFM32 comprises 32 items that evaluate physical function in three dimensions: D1 function related to standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and &quot;normally&quot;. The 32 scores are summed and expressed on a 0-100 scale for the MFM32 total score. Higher scores indicate increased motor function. Logistic regression analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
        <time_frame>At Month 12</time_frame>
        <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing MFM32 total score at Baseline were not included in the analysis. Missing results at Month 12 are considered as non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Risdiplam</title>
            <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percentage of Participants Who Achieve Stabilization or Improvement (Defined as &gt;= 0) in the Total Motor Function Measure (MFM-32) Score at Month 12</title>
          <description>The MFM32 comprises 32 items that evaluate physical function in three dimensions: D1 function related to standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and &quot;normally&quot;. The 32 scores are summed and expressed on a 0-100 scale for the MFM32 total score. Higher scores indicate increased motor function. Logistic regression analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
          <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing MFM32 total score at Baseline were not included in the analysis. Missing results at Month 12 are considered as non-responders.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6" lower_limit="60.72" upper_limit="78.41"/>
                    <measurement group_id="O2" value="54.2" lower_limit="40.68" upper_limit="67.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Logistic Regression Model. The variables included in the logistic regression are: baseline total score, treatment and age group.</non_inferiority_desc>
            <p_value>0.0430</p_value>
            <method>Wald test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>3.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Percentage of Participants Who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM-32 Score at Month 12</title>
        <description>The MFM32 comprises 32 items that evaluate physical function in three dimensions: D1 standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0-cannot initiate the task or maintain the starting position; 1-performs the task partially; 2-performs the task incompletely or imperfectly; 3-performs the task fully and &quot;normally&quot;. The 32 scores are summed and expressed on a 0-100 scale for the total score. Higher scores indicate increased motor function. Standard error of measurement (SEM) is derived using 32 items scores and total scores at baseline. Change from baseline &gt; = one SEM is equivalent to a change &gt;= 4. Logistic regression analysis was performed based on efficacy hypothetical estimand included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
        <time_frame>At Month 12</time_frame>
        <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing MFM32 total score at Baseline were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Risdiplam</title>
            <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percentage of Participants Who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM-32 Score at Month 12</title>
          <description>The MFM32 comprises 32 items that evaluate physical function in three dimensions: D1 standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0-cannot initiate the task or maintain the starting position; 1-performs the task partially; 2-performs the task incompletely or imperfectly; 3-performs the task fully and &quot;normally&quot;. The 32 scores are summed and expressed on a 0-100 scale for the total score. Higher scores indicate increased motor function. Standard error of measurement (SEM) is derived using 32 items scores and total scores at baseline. Change from baseline &gt; = one SEM is equivalent to a change &gt;= 4. Logistic regression analysis was performed based on efficacy hypothetical estimand included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
          <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing MFM32 total score at Baseline were not included in the analysis.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7" lower_limit="20.65" upper_limit="37.88"/>
                    <measurement group_id="O2" value="16.9" lower_limit="8.44" upper_limit="28.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Change From Baseline in the MFM-32 Domain 1 (D1) Score at Month 12</title>
        <description>The MFM32 comprises 32 items that evaluate physical function in three dimensions: D1 function related to standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and &quot;normally&quot;. The D1 items score are summed and expressed on 0-100 scale for the MFM D1 total score. Higher scores indicate increased motor function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
        <time_frame>Baseline (Day-1) and Month 12</time_frame>
        <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing MFM32 D1 score at Baseline were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Risdiplam</title>
            <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Change From Baseline in the MFM-32 Domain 1 (D1) Score at Month 12</title>
          <description>The MFM32 comprises 32 items that evaluate physical function in three dimensions: D1 function related to standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and &quot;normally&quot;. The D1 items score are summed and expressed on 0-100 scale for the MFM D1 total score. Higher scores indicate increased motor function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
          <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing MFM32 D1 score at Baseline were not included in the analysis.</population>
          <units>Scores on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" lower_limit="-0.12" upper_limit="0.87"/>
                    <measurement group_id="O2" value="-0.26" lower_limit="-0.94" upper_limit="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.</non_inferiority_desc>
            <p_value>0.1328</p_value>
            <method>Mixed Model Repeated Measure Analysis</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.20</ci_lower_limit>
            <ci_upper_limit>1.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Change From Baseline in the MFM-32 Domain 2 (D2) Score at Month 12</title>
        <description>The MFM32 comprises 32 items that evaluate physical function in three dimensions: D1 function related to standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and &quot;normally&quot;. The D2 items score are summed and expressed on 0-100 scale for the MFM D2 total score. Higher scores indicate increased motor function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
        <time_frame>Baseline (Day-1) and Month 12</time_frame>
        <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing MFM32 D2 score at Baseline were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Risdiplam</title>
            <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Change From Baseline in the MFM-32 Domain 2 (D2) Score at Month 12</title>
          <description>The MFM32 comprises 32 items that evaluate physical function in three dimensions: D1 function related to standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and &quot;normally&quot;. The D2 items score are summed and expressed on 0-100 scale for the MFM D2 total score. Higher scores indicate increased motor function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
          <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing MFM32 D2 score at Baseline were not included in the analysis.</population>
          <units>Scores on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" lower_limit="-0.38" upper_limit="2.46"/>
                    <measurement group_id="O2" value="-0.93" lower_limit="-2.87" upper_limit="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.</non_inferiority_desc>
            <p_value>0.1030</p_value>
            <method>Mixed Model Repeated Measure Analysis</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>1.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.40</ci_lower_limit>
            <ci_upper_limit>4.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Change From Baseline in the MFM-32 Domain 3 (D3) Score at Month 12</title>
        <description>The MFM32 comprises 32 items that evaluate physical function in three dimensions: D1 function related to standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and &quot;normally&quot;. The D3 items score are summed and expressed on 0-100 scale for the MFM D3 total score. Higher scores indicate increased motor function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
        <time_frame>Baseline (Day-1) and Month 12</time_frame>
        <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing MFM32 D3 score at Baseline were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Risdiplam</title>
            <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Change From Baseline in the MFM-32 Domain 3 (D3) Score at Month 12</title>
          <description>The MFM32 comprises 32 items that evaluate physical function in three dimensions: D1 function related to standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and &quot;normally&quot;. The D3 items score are summed and expressed on 0-100 scale for the MFM D3 total score. Higher scores indicate increased motor function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
          <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing MFM32 D3 score at Baseline were not included in the analysis.</population>
          <units>Scores on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68" lower_limit="2.31" upper_limit="5.04"/>
                    <measurement group_id="O2" value="1.34" lower_limit="-0.54" upper_limit="3.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.</non_inferiority_desc>
            <p_value>0.0451</p_value>
            <method>Mixed Model Repeated Measure Analysis</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>2.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.05</ci_lower_limit>
            <ci_upper_limit>4.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Change From Baseline in the Total Combined Scores of MFM-32 Domains 1 and 2 at Month 12</title>
        <description>The MFM32 comprises 32 items that evaluate physical function in three dimensions: D1 function related to standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and &quot;normally&quot;. The D1+D2 items score are summed and expressed on 0-100 scale for the MFM D1+D2 total score. Higher scores indicate increased motor function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
        <time_frame>Baseline (Day-1) and Month 12</time_frame>
        <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing MFM32 D1+D2 scores at Baseline were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Risdiplam</title>
            <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Change From Baseline in the Total Combined Scores of MFM-32 Domains 1 and 2 at Month 12</title>
          <description>The MFM32 comprises 32 items that evaluate physical function in three dimensions: D1 function related to standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and &quot;normally&quot;. The D1+D2 items score are summed and expressed on 0-100 scale for the MFM D1+D2 total score. Higher scores indicate increased motor function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
          <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing MFM32 D1+D2 scores at Baseline were not included in the analysis.</population>
          <units>Scores on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" lower_limit="-0.07" upper_limit="1.45"/>
                    <measurement group_id="O2" value="-0.59" lower_limit="-1.64" upper_limit="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.</non_inferiority_desc>
            <p_value>0.0489</p_value>
            <method>Mixed Model Repeated Measure Analysis</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>1.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>2.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Change From Baseline in the Total Combined Scores of MFM-32 Domains 2 and 3 at Month 12</title>
        <description>The MFM32 comprises 32 items that evaluate physical function in three dimensions: D1 function related to standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and &quot;normally&quot;. The D2+D3 items score are summed and expressed on 0-100 scale for the MFM D2+D3 total score. Higher scores indicate increased motor function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
        <time_frame>Baseline (Day-1) and Month 12</time_frame>
        <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing MFM32 D2+D3 scores at Baseline were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Risdiplam</title>
            <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Change From Baseline in the Total Combined Scores of MFM-32 Domains 2 and 3 at Month 12</title>
          <description>The MFM32 comprises 32 items that evaluate physical function in three dimensions: D1 function related to standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and &quot;normally&quot;. The D2+D3 items score are summed and expressed on 0-100 scale for the MFM D2+D3 total score. Higher scores indicate increased motor function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
          <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing MFM32 D2+D3 scores at Baseline were not included in the analysis.</population>
          <units>Scores on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" lower_limit="0.84" upper_limit="3.20"/>
                    <measurement group_id="O2" value="-0.14" lower_limit="-1.76" upper_limit="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.</non_inferiority_desc>
            <p_value>0.0326</p_value>
            <method>Mixed Model Repeated Measure Analysis</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>2.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.18</ci_lower_limit>
            <ci_upper_limit>4.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12 in Participants Aged 6-25 Years</title>
        <description>Spirometry is a pulmonary function test that assesses how the lungs work by measuring how much air moves through the airways. Spirometry was performed by all participants aged 6 or older. Forced expiratory volume (FEV1) is the volume forcefully exhaled in the first second of the forced vital capacity test. The best % predicted value out of all attempts were used for the analysis. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
        <time_frame>Baseline (Day-1) and Month 12</time_frame>
        <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing FEV1 data at Baseline were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Risdiplam</title>
            <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12 in Participants Aged 6-25 Years</title>
          <description>Spirometry is a pulmonary function test that assesses how the lungs work by measuring how much air moves through the airways. Spirometry was performed by all participants aged 6 or older. Forced expiratory volume (FEV1) is the volume forcefully exhaled in the first second of the forced vital capacity test. The best % predicted value out of all attempts were used for the analysis. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
          <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing FEV1 data at Baseline were not included in the analysis.</population>
          <units>Percentage Predicted</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.22" lower_limit="-7.49" upper_limit="-0.96"/>
                    <measurement group_id="O2" value="-1.35" lower_limit="-5.91" upper_limit="3.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.</non_inferiority_desc>
            <p_value>0.3029</p_value>
            <method>Mixed Model Repeated Measure Analysis</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-2.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.36</ci_lower_limit>
            <ci_upper_limit>2.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Change From Baseline in the Peak Cough Flow (PCF) at Month 12 in Participants Aged 6-25 Years</title>
        <description>Spirometry is a pulmonary function test that assesses how the lungs work by measuring how much air moves through the airways. Spirometry was performed by all participants aged 6 or older. Peak cough flow (PCF) is an assessment of cough strength. The best % predicted value out of all attempts were used for the analysis MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
        <time_frame>Baseline (Day-1) and Month 12</time_frame>
        <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing PCF data at Baseline were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Risdiplam</title>
            <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Change From Baseline in the Peak Cough Flow (PCF) at Month 12 in Participants Aged 6-25 Years</title>
          <description>Spirometry is a pulmonary function test that assesses how the lungs work by measuring how much air moves through the airways. Spirometry was performed by all participants aged 6 or older. Peak cough flow (PCF) is an assessment of cough strength. The best % predicted value out of all attempts were used for the analysis MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
          <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing PCF data at Baseline were not included in the analysis.</population>
          <units>Percent Predicted</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" lower_limit="-1.18" upper_limit="3.31"/>
                    <measurement group_id="O2" value="-0.22" lower_limit="-3.27" upper_limit="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.</non_inferiority_desc>
            <p_value>0.4937</p_value>
            <method>Mixed Model Repeated Measure Analysis</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>1.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.42</ci_lower_limit>
            <ci_upper_limit>4.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Change From Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12</title>
        <description>The Sniff Nasal Inspiratory Pressure (SNIP) is a volitional, non-invasive test of inspiratory muscle strength that has been successfully applied to children &gt; 2 years of age. Advantages include the simplicity of the maneuver and the absence of a mouthpiece, which is particularly helpful for participants with SMA, who may have bulbar weakness. SNIP also has the advantage of measuring inspiratory pressure during a natural maneuver that is easily performed even by young children with neuromuscular disorders. The best % predicted value out of all attempts were used for the analysis. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
        <time_frame>Baseline (Day-1) and Month 12</time_frame>
        <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing SNIP data at Baseline were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Risdiplam</title>
            <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Change From Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12</title>
          <description>The Sniff Nasal Inspiratory Pressure (SNIP) is a volitional, non-invasive test of inspiratory muscle strength that has been successfully applied to children &gt; 2 years of age. Advantages include the simplicity of the maneuver and the absence of a mouthpiece, which is particularly helpful for participants with SMA, who may have bulbar weakness. SNIP also has the advantage of measuring inspiratory pressure during a natural maneuver that is easily performed even by young children with neuromuscular disorders. The best % predicted value out of all attempts were used for the analysis. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
          <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing SNIP data at Baseline were not included in the analysis.</population>
          <units>Percentage Predicted</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.42" lower_limit="0.22" upper_limit="6.62"/>
                    <measurement group_id="O2" value="1.07" lower_limit="-3.42" upper_limit="5.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.</non_inferiority_desc>
            <p_value>0.3967</p_value>
            <method>Mixed Model Repeated Measure Analysis</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>2.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.11</ci_lower_limit>
            <ci_upper_limit>7.80</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Change From Baseline in Maximal Inspiratory Pressure (MIP) at Month 12 in Participants Aged 6-25 Years</title>
        <description>The maximal inspiratory pressure (MIP) is a non-invasive test of muscle strength, which measures the maximum strength of the diaphragm and other inspiratory muscles. MIP was measured in participants aged 6 or older. Participants were asked to perform a forceful inspiration against an occluded mouth piece. The best % predicted value out of all attempts were used for the analysis. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
        <time_frame>Baseline (Day-1) and Month 12</time_frame>
        <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing MIP data at Baseline were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Risdiplam</title>
            <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Change From Baseline in Maximal Inspiratory Pressure (MIP) at Month 12 in Participants Aged 6-25 Years</title>
          <description>The maximal inspiratory pressure (MIP) is a non-invasive test of muscle strength, which measures the maximum strength of the diaphragm and other inspiratory muscles. MIP was measured in participants aged 6 or older. Participants were asked to perform a forceful inspiration against an occluded mouth piece. The best % predicted value out of all attempts were used for the analysis. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
          <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing MIP data at Baseline were not included in the analysis.</population>
          <units>Percentage Predicted</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" lower_limit="-6.13" upper_limit="10.11"/>
                    <measurement group_id="O2" value="-0.97" lower_limit="-12.33" upper_limit="10.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.</non_inferiority_desc>
            <p_value>0.6704</p_value>
            <method>Mixed Model Repeated Measure Analysis</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>2.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.78</ci_lower_limit>
            <ci_upper_limit>16.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Change From Baseline in Maximal Expiratory Pressure (MEP) at Month 12 in Participants Aged 6-25 Years</title>
        <description>The maximal expiratory pressure (MEP) is a non-invasive test of muscle strength, which measures the maximum strength of the abdominal muscles and other expiratory muscles. MEP was measured in participants aged 6 or older. Participants were asked to perform a forceful inspiration against an occluded mouth piece. The best % predicted value out of all attempts were used for the analysis. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
        <time_frame>Baseline (Day-1) and Month 12</time_frame>
        <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing MEP data at Baseline were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Risdiplam</title>
            <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Change From Baseline in Maximal Expiratory Pressure (MEP) at Month 12 in Participants Aged 6-25 Years</title>
          <description>The maximal expiratory pressure (MEP) is a non-invasive test of muscle strength, which measures the maximum strength of the abdominal muscles and other expiratory muscles. MEP was measured in participants aged 6 or older. Participants were asked to perform a forceful inspiration against an occluded mouth piece. The best % predicted value out of all attempts were used for the analysis. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
          <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing MEP data at Baseline were not included in the analysis.</population>
          <units>Percentage Predicted</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.75" lower_limit="-6.22" upper_limit="0.72"/>
                    <measurement group_id="O2" value="-2.33" lower_limit="-7.21" upper_limit="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.</non_inferiority_desc>
            <p_value>0.8856</p_value>
            <method>Mixed Model Repeated Measure Analysis</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.30</ci_lower_limit>
            <ci_upper_limit>5.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Change From Baseline in the Participant-Reported SMA Independence Scale (SMAIS) Total Score at Month 12</title>
        <description>The SMAIS was developed specifically for SMA participants in order to assess function-related independence. It contains 29 items, assessing the amount of assistance required from another individual to perform daily activities such as eating, or bathing. Each item is scored on a 0-4 scale (with an additional option to indicate that an item is non-applicable). The SMAIS total score ranging from 0-44 is obtained based on 22 items with each item on the 0-2 scale. Lower scores indicate greater dependence on another individual. The SMAIS was completed by participants aged 12 years or older and caregivers of participants aged 2-25 years. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
        <time_frame>Baseline (Day-1) and Month 12</time_frame>
        <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing SMAIS total score at Baseline were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Risdiplam</title>
            <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Change From Baseline in the Participant-Reported SMA Independence Scale (SMAIS) Total Score at Month 12</title>
          <description>The SMAIS was developed specifically for SMA participants in order to assess function-related independence. It contains 29 items, assessing the amount of assistance required from another individual to perform daily activities such as eating, or bathing. Each item is scored on a 0-4 scale (with an additional option to indicate that an item is non-applicable). The SMAIS total score ranging from 0-44 is obtained based on 22 items with each item on the 0-2 scale. Lower scores indicate greater dependence on another individual. The SMAIS was completed by participants aged 12 years or older and caregivers of participants aged 2-25 years. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
          <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Participants with missing SMAIS total score at Baseline were not included in the analysis.</population>
          <units>Scores on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" lower_limit="-0.26" upper_limit="2.35"/>
                    <measurement group_id="O2" value="-0.40" lower_limit="-2.13" upper_limit="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.</non_inferiority_desc>
            <p_value>0.1778</p_value>
            <method>Mixed Model Repeated Measure Analysis</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>1.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.68</ci_lower_limit>
            <ci_upper_limit>3.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Percentage of Participants Rated by Clinicians as No Change or Improved in the Clinical Global Impression of Change (CGI-C) Scale Ratings at Month 12</title>
        <description>The CGI-C is used to score a clinician's impression of a participant's change in global health. It is a single item measure of change in global health, using seven response options: &quot;very much improved&quot;, &quot;much improved&quot;, &quot;minimally improved&quot;, &quot;no change&quot;, &quot;minimally worse&quot;, &quot;much worse&quot;, and &quot;very much worse&quot;. Participants considered as &quot;no change or improved&quot; included responses of &quot;no change&quot;, &quot;very much improved&quot;, &quot;much improved&quot; and &quot;minimally improved&quot;. Logistic regression analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
        <time_frame>At Month 12</time_frame>
        <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Missing results at Month 12 are considered as non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Risdiplam</title>
            <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percentage of Participants Rated by Clinicians as No Change or Improved in the Clinical Global Impression of Change (CGI-C) Scale Ratings at Month 12</title>
          <description>The CGI-C is used to score a clinician's impression of a participant's change in global health. It is a single item measure of change in global health, using seven response options: &quot;very much improved&quot;, &quot;much improved&quot;, &quot;minimally improved&quot;, &quot;no change&quot;, &quot;minimally worse&quot;, &quot;much worse&quot;, and &quot;very much worse&quot;. Participants considered as &quot;no change or improved&quot; included responses of &quot;no change&quot;, &quot;very much improved&quot;, &quot;much improved&quot; and &quot;minimally improved&quot;. Logistic regression analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12.</description>
          <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Missing results at Month 12 are considered as non-responders.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.8" lower_limit="79.18" upper_limit="92.49"/>
                    <measurement group_id="O2" value="83.3" lower_limit="73.07" upper_limit="93.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CGI No Change or Improved</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Logistic Regression Model. The variables included in the logistic regression are: baseline total score, treatment and age group.</non_inferiority_desc>
            <p_value>0.6636</p_value>
            <method>Wald-test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>2.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Percentage of Participants Who Experience at Least One Disease-Related Adverse Event at Month 12</title>
        <description>Disease-related adverse events (AEs) were identified by applying two different types of baskets to the AE dataset: Narrow prospectively defined baskets of MedDRA lowest level terms. This basket was defined based on a group of CDC terms selected from an age and gender matched case control study comparing CDC code rates observed in participants with and without SMA using commercially available insurance claim data (CLAIMS and Market scan data). The lowest level terms included in each basket, coded using the latest version of MedDRA; Broad prospectively defined basket with events selected at preferred term level from all AEs reported in ongoing clinical trials up to January 2019, i.e., prior to unblinding of Part 2 of Study BP39055.</description>
        <time_frame>Baseline up to Month 12 (Week 52; up to CCOD of 06 September 2019)</time_frame>
        <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Risdiplam</title>
            <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percentage of Participants Who Experience at Least One Disease-Related Adverse Event at Month 12</title>
          <description>Disease-related adverse events (AEs) were identified by applying two different types of baskets to the AE dataset: Narrow prospectively defined baskets of MedDRA lowest level terms. This basket was defined based on a group of CDC terms selected from an age and gender matched case control study comparing CDC code rates observed in participants with and without SMA using commercially available insurance claim data (CLAIMS and Market scan data). The lowest level terms included in each basket, coded using the latest version of MedDRA; Broad prospectively defined basket with events selected at preferred term level from all AEs reported in ongoing clinical trials up to January 2019, i.e., prior to unblinding of Part 2 of Study BP39055.</description>
          <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Narrow Basket AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7" lower_limit="37.51" upper_limit="55.99"/>
                    <measurement group_id="O2" value="53.3" lower_limit="40.00" upper_limit="66.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Broad Basket AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0" lower_limit="55.76" upper_limit="73.48"/>
                    <measurement group_id="O2" value="60.0" lower_limit="46.54" upper_limit="72.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Number of Disease-related Adverse Events Per Patient-years at Month 12</title>
        <description>Disease-related AEs were collected through the AE reporting of the study, and the disease-related AE rate was adjusted for patient years (AE rate per 100 patient-years). They were identified by applying two different types of baskets to the AE dataset: Narrow prospectively defined baskets of MedDRA lowest level terms and Broad prospectively defined basket with events selected at preferred term level from all AEs reported in ongoing clinical trials up to January 2019, i.e., prior to unblinding of Part 2 of Study BP39055.</description>
        <time_frame>Baseline up to Month 12 (Week 52; up to CCOD of 06 September 2019)</time_frame>
        <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Risdiplam</title>
            <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Disease-related Adverse Events Per Patient-years at Month 12</title>
          <description>Disease-related AEs were collected through the AE reporting of the study, and the disease-related AE rate was adjusted for patient years (AE rate per 100 patient-years). They were identified by applying two different types of baskets to the AE dataset: Narrow prospectively defined baskets of MedDRA lowest level terms and Broad prospectively defined basket with events selected at preferred term level from all AEs reported in ongoing clinical trials up to January 2019, i.e., prior to unblinding of Part 2 of Study BP39055.</description>
          <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2.</population>
          <units>Number of Events per 100 Patient-Years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Narrow Basket AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.51" lower_limit="84.23" upper_limit="121.29"/>
                    <measurement group_id="O2" value="119.77" lower_limit="93.71" upper_limit="150.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Broad Basket AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217.29" lower_limit="191.63" upper_limit="245.42"/>
                    <measurement group_id="O2" value="199.61" lower_limit="165.50" upper_limit="238.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
        <time_frame>Day 1 on risdiplam up to end of study (up to approximately 7 years)</time_frame>
        <posting_date>09/2024</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) in the Placebo-Controlled Period</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
        <time_frame>Day 1 up to 12 months of the placebo-controlled period</time_frame>
        <population>All participants in Part 2 who receive at least one dose of study medication (risdiplam or placebo) were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Risdiplam</title>
            <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) in the Placebo-Controlled Period</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
          <population>All participants in Part 2 who receive at least one dose of study medication (risdiplam or placebo) were included in the safety population.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With at Least One AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5"/>
                    <measurement group_id="O2" value="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With at Least One SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Percentage of Participants With Treatment Discontinuation Due to Adverse Events (AEs) and Serious Adverse Events (SAEs) in the Placebo-Controlled Period</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
        <time_frame>Day 1 up to 12 months of the placebo-controlled period</time_frame>
        <population>All participants in Part 2 who received at least one dose of study medication (risdiplam or placebo) were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Risdiplam</title>
            <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percentage of Participants With Treatment Discontinuation Due to Adverse Events (AEs) and Serious Adverse Events (SAEs) in the Placebo-Controlled Period</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
          <population>All participants in Part 2 who received at least one dose of study medication (risdiplam or placebo) were included in the safety population.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Due to AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Due to SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Number of Participants Aged 6-25 Years With Suicidal Ideation Based on Columbia-Suicide Severity Rating Scale (C-SSRS) in the Placebo-Controlled Period</title>
        <description>The Columbia Suicide Severity Rating Scale (C-SSRS) is used to assess the lifetime suicidality of a participant (C-SSRS baseline) as well as any new instances of suicidality (C-SSRS since last visit). The structured interview prompts recollection of suicidal ideation, including the intensity of the ideation, behavior, and attempts with actual/potential lethality. The C-SSRS assessments results were collected for participants aged 6 years and older.</description>
        <time_frame>Day 1 up to 12 months of the placebo-controlled period</time_frame>
        <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Data was collected for participants aged 6-25 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Risdiplam</title>
            <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants Aged 6-25 Years With Suicidal Ideation Based on Columbia-Suicide Severity Rating Scale (C-SSRS) in the Placebo-Controlled Period</title>
          <description>The Columbia Suicide Severity Rating Scale (C-SSRS) is used to assess the lifetime suicidality of a participant (C-SSRS baseline) as well as any new instances of suicidality (C-SSRS since last visit). The structured interview prompts recollection of suicidal ideation, including the intensity of the ideation, behavior, and attempts with actual/potential lethality. The C-SSRS assessments results were collected for participants aged 6 years and older.</description>
          <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Data was collected for participants aged 6-25 years.</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wish to be Dead</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-specific Active Suicidal Thoughts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ideation with Any Methods, No Intent to Act</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ideation with Some Intent to Act, No Plan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ideation with Specific Plan and Intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Number of Participants Aged 6-25 Years With Suicidal Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) in the Placebo-Controlled Period</title>
        <description>The Columbia Suicide Severity Rating Scale (C-SSRS) is used to assess the lifetime suicidality of a participant (C-SSRS baseline) as well as any new instances of suicidality (C-SSRS since last visit). The structured interview prompts recollection of suicidal ideation, including the intensity of the ideation, behavior, and attempts with actual/potential lethality. The C-SSRS assessments results were collected for participants aged 6 years and older.</description>
        <time_frame>Day 1 up to 12 months of the placebo-controlled period</time_frame>
        <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Data was collected for participants aged 6-25 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Risdiplam</title>
            <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants Aged 6-25 Years With Suicidal Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) in the Placebo-Controlled Period</title>
          <description>The Columbia Suicide Severity Rating Scale (C-SSRS) is used to assess the lifetime suicidality of a participant (C-SSRS baseline) as well as any new instances of suicidality (C-SSRS since last visit). The structured interview prompts recollection of suicidal ideation, including the intensity of the ideation, behavior, and attempts with actual/potential lethality. The C-SSRS assessments results were collected for participants aged 6 years and older.</description>
          <population>The intent-to-treat (ITT) population defined as all randomized participants in Part 2. Data was collected for participants aged 6-25 years.</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Preparatory Acts or Behavior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aborted Attempt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interrupted Attempt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Actual Attempt (non-fatal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Completed Suicide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood</title>
        <time_frame>Part 2: Days -1, 1, 7, 28, 120, 246, 365, 729</time_frame>
        <posting_date>09/2024</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival of Motor Neuron (SMN) Protein Levels in Blood</title>
        <time_frame>Part 2: Days -1, 7, 28, 120, 246, 365, 729</time_frame>
        <posting_date>09/2024</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam</title>
        <time_frame>Part 1 and 2: 1, 2, 4, 6 hours post dose on Day 1; Pre-dose (Hour 0) on Days 7, 14, 56 (Part 2), 120, 246, 490, 729; pre-dose (Hour 0) and 1, 2, 4, 6 hours post dose on Days 28, 56 (Part 1), 365, 609</time_frame>
        <posting_date>09/2024</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1 and 2: Area Under the Curve (AUC) of Risdiplam</title>
        <time_frame>Part 1 and 2: 1, 2, 4, 6 hours post dose on Day 1; Pre-dose (Hour 0) on Days 7, 14, 56 (Part 2), 120, 246, 490, 729; pre-dose (Hour 0) and 1, 2, 4, 6 hours post dose on Days 28, 56 (Part 1), 365, 609</time_frame>
        <posting_date>09/2024</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam</title>
        <time_frame>Part 1 and 2: Pre-dose (Hour 0) on Days 7, 14, 28, 56, 120, 246, 365, 490, 609, 729</time_frame>
        <posting_date>09/2024</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Part 1: Day 1 up to at least 12 months (up to CCOD of 09 January 2019); Part 2: At least 12 months (up to CCOD of 06 September 2019)</time_frame>
      <desc>All participants in Part 1 or who received at least one dose of study medication (risdiplam or placebo) whether prematurely withdrawn or not were included in the safety population. All participants in Part 2 who receive at least one dose of study medication (risdiplam or placebo) were included in the safety population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part 1 Group A: Adolescents and Adults (3 mg Risdiplam)</title>
          <description>Adolescent and adult participants aged 12-25 years received risdiplam for at least 12 weeks during the placebo-controlled period.</description>
        </group>
        <group group_id="E2">
          <title>Part 1 Group A: Adolescents and Adults (5 mg Risdiplam)</title>
          <description>Adolescent and adult participants aged 12-25 years received risdiplam for at least 12 weeks during the placebo-controlled period.</description>
        </group>
        <group group_id="E3">
          <title>Part 1 Group A: Adolescents and Adults (Placebo-Control Period Pooled)</title>
          <description>Adolescent and adult participants aged 12-25 years received placebo matching to risdiplam for at least 12 weeks during the placebo-controlled period.</description>
        </group>
        <group group_id="E4">
          <title>Part 1 Group B: Children (0.02 mg/kg Risdiplam)</title>
          <description>Children aged 2-11 years received risdiplam for at least 12 weeks during the placebo-controlled period.</description>
        </group>
        <group group_id="E5">
          <title>Part 1 Group B: Children (0.05 mg/kg Risdiplam)</title>
          <description>Children aged 2-11 years received risdiplam for at least 12 weeks during the placebo-controlled period.</description>
        </group>
        <group group_id="E6">
          <title>Part 1 Group B: Children (0.15 mg/kg Risdiplam)</title>
          <description>Children aged 2-11 years received risdiplam for at least 12 weeks during the placebo-controlled period.</description>
        </group>
        <group group_id="E7">
          <title>Part 1 Group B: Children (0.25 mg/kg Risdiplam)</title>
          <description>Children aged 2-11 years received risdiplam for at least 12 weeks during the placebo-controlled period.</description>
        </group>
        <group group_id="E8">
          <title>Part 1 Group B: Children (Placebo-Control Period Pooled)</title>
          <description>Children aged 2-11 years received placebo matching to risdiplam for at least 12 weeks during the placebo-controlled period.</description>
        </group>
        <group group_id="E9">
          <title>Part 1 Group A: OLE</title>
          <description>Once the placebo-controlled period was completed and Part 2 dose was selected, adolescents and adults switched to Part 2 dose and were treated in an open-label extension (OLE) phase.</description>
        </group>
        <group group_id="E10">
          <title>Part 1 Group B: OLE</title>
          <description>Once the placebo-controlled period was completed and Part 2 dose was selected, children switched to Part 2 dose and were treated in an open-label extension (OLE) phase.</description>
        </group>
        <group group_id="E11">
          <title>Part 2: Risdiplam</title>
          <description>Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20 kg for 12 months.</description>
        </group>
        <group group_id="E12">
          <title>Part 2: Placebo</title>
          <description>Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) &gt;/=20kg or 0.25 mg/kg for participants with a BW &lt;20) in a blinded manner and participants will continue with treatment and observations.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="26" subjects_at_risk="120"/>
                <counts group_id="E12" subjects_affected="11" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Medical device pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Lymph gland infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="12" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Lung operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Renal stone removal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="23" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="102" subjects_at_risk="120"/>
                <counts group_id="E12" subjects_affected="50" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="5" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Motion sickness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Eczema eyelids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="12" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E12" events="8" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E11" events="7" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E12" events="3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="11" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E12" events="7" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="29" subjects_affected="22" subjects_at_risk="120"/>
                <counts group_id="E12" events="8" subjects_affected="8" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="13" subjects_affected="11" subjects_at_risk="120"/>
                <counts group_id="E12" events="6" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E7" events="4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="10" subjects_affected="7" subjects_at_risk="31"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="38" subjects_affected="18" subjects_at_risk="120"/>
                <counts group_id="E12" events="29" subjects_affected="15" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="4" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hyperchlorhydria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Oral mucosal erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Tongue oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Lip pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E7" events="12" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E8" events="5" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E9" events="20" subjects_affected="11" subjects_at_risk="31"/>
                <counts group_id="E10" events="6" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E11" events="45" subjects_affected="27" subjects_at_risk="120"/>
                <counts group_id="E12" events="21" subjects_affected="11" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hyperpyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Catheter site extravasation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" events="5" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="9" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="9" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E12" events="12" subjects_affected="10" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="6" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E12" events="5" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="11" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E12" events="7" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E12" events="4" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E7" events="6" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="10" subjects_affected="7" subjects_at_risk="31"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="57" subjects_affected="32" subjects_at_risk="120"/>
                <counts group_id="E12" events="22" subjects_affected="16" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="9" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="5" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="12" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E12" events="10" subjects_affected="7" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="9" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E12" events="4" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="4" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E12" events="5" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E7" events="7" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="16" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="58" subjects_affected="39" subjects_at_risk="120"/>
                <counts group_id="E12" events="31" subjects_affected="20" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="7" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="5" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Laryngitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Scarlet fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Groin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ear infection fungal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Erythema infectiosum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E12" events="3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="5" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="10" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="6" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E12" events="5" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="15" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="12" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E11" events="5" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E12" events="4" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="12" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" events="5" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="12" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E10" events="9" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E11" events="139" subjects_affected="25" subjects_at_risk="120"/>
                <counts group_id="E12" events="46" subjects_affected="11" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Initial insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Amenorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="17" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="9" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E7" events="9" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E8" events="4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" events="19" subjects_affected="9" subjects_at_risk="31"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E11" events="29" subjects_affected="17" subjects_at_risk="120"/>
                <counts group_id="E12" events="21" subjects_affected="13" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="4" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E12" events="5" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="6" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E12" events="9" subjects_affected="8" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="7" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="6" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="4" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" events="6" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E10" events="4" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="6" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="11" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="5" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="4" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Palmar erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Skin induration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800 821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

